Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 24  •  04:00PM ET
0.9860
Dollar change
-0.0062
Percentage change
-0.62
%
Index- P/E- EPS (ttm)-7.92 Insider Own45.23% Shs Outstand23.18M Perf Week0.22%
Market Cap23.10M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.83M Perf Month-22.36%
Enterprise Value25.19M PEG- EPS next Q- Inst Own4.96% Short Float6.06% Perf Quarter-29.87%
Income-130.98M P/S- EPS this Y- Inst Trans-7.99% Short Ratio0.20 Perf Half Y-71.76%
Sales0.00M P/B- EPS next Y- ROA-203.39% Short Interest0.78M Perf YTD-88.20%
Book/sh-0.56 P/C37.26 EPS next 5Y- ROE-308.01% 52W High14.00 -92.96% Perf Year-93.99%
Cash/sh0.03 P/FCF- EPS past 3/5Y20.66% -34.35% ROIC- 52W Low0.81 21.73% Perf 3Y-92.59%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.46% 13.43% Perf 5Y-96.83%
Dividend TTM- EV/Sales- EPS Y/Y TTM23.38% Oper. Margin- ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.04 Sales Y/Y TTM- Profit Margin- RSI (14)42.48 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.04 EPS Q/Q104.53% SMA20-14.38% Beta0.37 Target Price-
Payout- Debt/Eq- Sales Q/Q- SMA50-11.13% Rel Volume0.01 Prev Close0.99
Employees29 LT Debt/Eq- Earnings- SMA200-63.34% Avg Volume3.89M Price0.99
IPOFeb 02, 2015 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume32,462 Change-0.62%
Dec-18-25 09:00AM
Dec-09-25 07:45AM
Nov-25-25 07:45AM
Nov-14-25 04:44PM
Nov-05-25 09:22AM
09:32AM Loading…
Oct-30-25 09:32AM
Oct-16-25 09:45AM
09:15AM
Oct-06-25 09:15AM
Sep-25-25 08:30AM
Sep-24-25 04:50PM
Sep-11-25 07:00AM
Sep-09-25 08:47AM
Sep-08-25 08:50AM
Sep-04-25 10:05AM
09:45AM Loading…
Aug-27-25 09:45AM
Aug-08-25 10:45AM
Jul-29-25 03:01PM
Jul-28-25 10:38AM
Jul-17-25 09:15AM
Jul-09-25 08:00AM
Jun-30-25 09:21AM
Jun-10-25 11:13AM
Jun-03-25 09:15AM
May-23-25 09:17AM
May-22-25 09:41PM
03:12PM
11:05AM
May-14-25 09:15AM
May-13-25 09:15AM
09:20AM Loading…
Apr-22-25 09:20AM
Apr-09-25 09:25AM
Apr-05-25 12:10PM
Apr-04-25 09:40AM
Mar-03-25 09:15AM
09:00AM
Feb-26-25 01:25PM
09:15AM
Feb-19-25 10:10AM
Jan-07-25 09:15AM
09:15AM
Jan-06-25 09:15AM
09:10AM
Dec-30-24 09:00AM
Dec-23-24 09:00AM
Dec-20-24 03:40PM
09:00AM
Nov-04-24 08:31AM
Oct-17-24 09:15AM
Oct-16-24 09:28AM
Sep-19-24 09:00AM
Sep-17-24 09:00AM
Sep-13-24 09:00AM
Sep-11-24 09:15AM
Jul-26-24 07:36AM
05:30AM
Jun-14-24 09:06AM
May-24-24 09:20AM
08:45AM
May-16-24 08:53AM
Apr-30-24 11:00AM
Apr-24-24 09:00AM
Apr-18-24 08:45AM
Mar-04-24 09:00PM
Feb-15-24 09:25AM
Feb-14-24 10:01AM
Feb-13-24 09:46AM
09:31AM
Jan-25-24 12:45PM
Jan-18-24 09:30AM
Jan-16-24 08:00AM
Nov-28-23 08:30AM
Nov-23-23 09:30AM
Nov-22-23 10:44AM
Nov-21-23 08:30AM
Nov-14-23 09:00AM
Nov-10-23 08:30AM
Nov-07-23 08:30AM
Oct-24-23 09:00AM
Oct-11-23 09:25AM
08:30AM
Oct-10-23 08:00AM
Oct-04-23 09:00AM
Oct-02-23 12:05PM
09:25AM
08:30AM
Sep-29-23 09:15AM
09:15AM
Sep-21-23 03:00PM
Sep-19-23 08:30AM
Sep-06-23 12:40AM
Aug-30-23 09:15AM
Aug-21-23 09:15AM
Aug-10-23 12:06AM
Aug-09-23 09:00AM
Jul-17-23 07:29AM
Jun-23-23 05:00PM
Jun-08-23 08:45AM
Apr-03-23 09:00AM
Mar-29-23 09:00AM
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.